Introduction {#Sec1}
============

Idiopathic pulmonary fibrosis (IPF) is a severe disease characterised by debilitating symptoms such as cough, fatigue, increasing and immobilising dyspnoea and is associated with a limited survival \[[@CR1], [@CR2]\]. IPF symptoms and outcomes are also strongly influenced by co-morbidities \[[@CR3], [@CR4]\]. The psychosocial impact of IPF is substantial for both patients and their caregivers \[[@CR1], [@CR5]\]. Recent reports have shown that in IPF patients health-related quality of life (QoL) is associated with clinical symptoms, duration of disease, physical activity, comorbidities, and disease severity \[[@CR6]--[@CR10]\] and may be prognostic \[[@CR11]\].

While current therapies aim to improve the disease course and to prolong life expectancy, less well understood is how best to improve an individual's health-related quality of life and psychosocial needs \[[@CR12]\]. To address this, patient-reported outcomes incorporating determination of health-related quality of life (QoL) assessments are increasingly used as important outcome measures, in clinical practice and in clinical trials \[[@CR6]\]. However, data on longitudinal determinations of QoL in IPF patients, especially in the real-life setting are sparse. Previously, we have reported on baseline characteristics and QoL status in patients enrolled in a large nationwide observational IPF registry (INSIGHTS-IPF) \[[@CR2], [@CR7]\]. In the present analyses, we report longitudinal data (with up to 36 months follow-up) for a range of QoL measures and examine changes in QoL outcomes and their relationship to clinical parameters.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The INSIGHTS-IPF ("Investigating significant health trends in idiopathic pulmonary fibrosis") registry is a nationwide, investigator-initiated cohort study, which has been continuously enrolling consecutive patients in routine clinical care across 19 pulmonary specialist centres in Germany since November 2012. Patients ≥18 years of age with a study-site diagnosis of IPF after provision of written informed consent can be enrolled, with no explicit exclusion criteria. The registry's structure, methodology and regulatory aspects, and a detailed description of the baseline characteristics of the patient cohort have been reported \[[@CR2], [@CR13], [@CR14]\]. Patients with a QoL assessment at baseline and at least one follow-up assessment were available for this study. The change in QoL was studied for 3 years after enrolment into the registry (i.e., 3-year follow-up), because of the currently limited number of patients (*n* = 24) with available QoL data for follow-up beyond this time-point.

Clinical and patient-reported outcome measures {#Sec4}
----------------------------------------------

Data were collected at enrolment (baseline) and at subsequent 6- to 12 months intervals. At each follow-up visit, all clinical events including hospitalisation and acute exacerbations (as judged by the treating physician), and death were recorded by each site. At these visits, a range of routine pulmonary function tests were documented, including forced vital capacity (FVC) % predicted, diffusing capacity of the lung for carbon monoxide (DL~CO~) % predicted, the forced expiratory volume in 1 s (FEV~1~), and six-minute walk distance (6MWD). The Gender, Age, Physiology (GAP) index was also determined. All patients completed the NYHA functional status and a range of QoL questionnaires as previously reported \[[@CR7]\]. These include the St. George's Respiratory Questionnaire (SGRQ), the University of California San Diego Shortness of Breath Questionnaire (USCD-SOBQ), the EuroQol five-dimensional questionnaire, recorded as a visual analogue scale (EQ-VAS), and the World Health Organization-5 Well-Being Index (WHO-5). At each visit, where possible the treating physician made and recorded their judgement of overall disease course (stable disease, slow progression, rapid progression) according to Behr et al. (2). Functional changes were categorized as stable/increased if FVC did not change or was improved by ≥0%, as a moderate decrease between \> 0--10% and a significant decrease in case of \> 10%.

All data were collected using an internet-based case report form (eCRF) with secure electronic data transfer to the central database. Quality measures included automated plausibility checks at data entry, statistical checks on data quality (focussing on missing values and outliers) as well as on-site monitoring and source data verification performed in the majority of centres (over 70%).

Data analysis {#Sec5}
-------------

Data were summarised by descriptive statistics including means and standard deviations and absolute and relative frequencies at baseline and each subsequent follow-up assessment. Baseline characteristics were compared by t-test for continuously distributed variables and Chi2 test for categorical variables between patients who were included in the analyses and excluded by missing QoL assessments. Linear mixed models were applied to investigate the change in QoL in follow-up with the study centres as cluster variable. Clinical characteristics such as lung function test at baseline (time invariant) and follow-up (time varying) were used to analyse possible associations with the change in QoL across time by linear mixed models. The association of mortality with QoL at the last available follow-up and change in QoL between baseline and last follow-up was analysed by Cox proportional hazard models. Hospitalisations for any reason and hospitalisations due to exacerbation in follow-up were investigated by linear mixed models. Multivariable regression models for mortality and hospitalisations included lung function test, the number of comorbidities, age and the physicians global judgement about disease activity as covariates. A *p*-value of lower than 0.05 was considered to be statistically significant.

Data were analysed with STATA 12.1 (StataCorp LP. Stata Statistical Software: Release 12. College Station, TX, USA).

Results {#Sec6}
=======

Patient characteristics {#Sec7}
-----------------------

Of 879 patients, a total of 424 patients provided QoL data at baseline and at least at one follow-up visit, and were included in these analyses. Baseline characteristics of this cohort are presented in Table [1](#Tab1){ref-type="table"}. Baseline characteristics for patients who were not included due to missing follow-up assessment of QoL -in comparison to the cohort reported here- are presented in Additional file [1](#MOESM1){ref-type="media"}: Table S4. For this the cohort, the patients mean age was 68.7 ± 9.1 years, 76.9% were male, and mean symptom duration was 3.7 ± 4.1 years, with 61.3% having disease for more than 6 months at registry enrolment; 60.4% of participants were former smokers with 38.0% never having smoked. Most patients (77.6%) had one or more comorbidities. At baseline, the IPF was judged by treating physicians as stable in 39.2% of patients, slowly progressing in 29.0% and rapidly progressing in 7.3%. Most patients were in NYHA functional class II/III at enrolment, with a mean 6MWD of 288 ± 200 m. Mean values for respiratory parameters were; FVC % predicted (75.9% ± 19.4), FEV~1~% (68.3% ± 17.4), and DL~CO~ % predicted (36.1% ± 15.9); 53.0% were in GAP index stage 2 and 28.2% in stage 3.Table 1Sociodemographic and clinical parameters of the patient cohort analysedPatient characteristicsn (%) / mean (SD)\
*n* = 424Female98 (23.1%)Age in years68.7 (9.1)Age at first symptom onset in years64.9 (10.3)Age at diagnosis in years66.8 (9.7)Duration since first symptoms in years3.7 (4.1)Disease duration in months2.0 (2.7)  \< 3 months124 (29.5%) 3 to \< 6 months39 (9.3%) More than 6 months258 (61.3%)Smoking status Never161 (38.0%) Former stopped256 (60.4%) Current7 (1.7%)Number of comorbidities None95 (22.4%) 1124 (29.3%) 2107 (25.2%) 363 (14.9%) 4+35 (8.3%)NHYA I28 (14.7%) II81 (42.6%) III76 (40.0%) IV5 (2.6%)Six-minute walk distance (m)287.7 (199.6)% FEV~1~68.3 (17.4)% FVC36.1 (15.9)% DL~CO~75.9 (19.4)GAP index4.7 (1.4) Stage I72 (18.8%) Stage II203 (53.0%) Stage III108 (28.2%)Overall physician's judgement of clinical course of IPF Stable disease166 (39.2%) Slow progression123 (29.0%) Rapid progression31 (7.3%) No judgement possible104 (24.5%)SGRQ45.9 (19.7)SGRQ symptoms55.9 (21.0)SGRQ activity59.7 (23.6)SGRQ impacts34.8 (20.7)UCSD-SOBQ43.9 (28.8)EQ-5D VAS62.6 (18.5)WHO-514.8 (5.7)Values are n (%) or mean (SD)*DL*~*CO*~ diffusing capacity of the lung for carbon monoxide, *EQ-5D VAS* EuroQol five-dimensional questionnaire, recorded as a visual analog scale, *FEV*~*1*~ Forced expiratory volume in 1 s, *FVC* forced vital capacity, *GAP index* Gender, Age, Physiology index, *IPF* idiopathic pulmonary fibrosis, *NYHA* New York Heart Association functional class, *SD* standard deviation, *SGRQ* St. George's Respiratory Questionnaire, *USCD-SOBQ* University of California San Diego Shortness of Breath Questionnaire, *WHO-5* World Health Organization-5 Well-Being Index

At baseline the mean SGRQ total score was 45.9 ± 19.7, with higher scores for the SGRQ activity domain (59.7 ± 23.6) than symptom or impact domains. Patient reported breathlessness with a mean USCD-SOBQ score of 43.9 ± 28.8. Mean EQ-5D VAS scores were 62.6 ± 1 8.5 with mean WHO-5 scores of 14.8 ± 5.7.

Change in QoL over time and associations to clinical parameters during follow up {#Sec8}
--------------------------------------------------------------------------------

The courses for QoL scores from baseline to last follow-up visit are shown in Fig. [1](#Fig1){ref-type="fig"} (and in online data supplement; Additional file [2](#MOESM2){ref-type="media"}: Table S1). Longitudinal data showed a significant increase in SGRQ total scores (beta = 1.47, 95% CI: 1.17 to 1.76; *p* \< 0.001) and UCSD-SOBQ score (beta = 3.63, 95% CI: 3.07 to 4.18; *p* \< 0.001) per half-year between baseline and 36-months follow-up (indicating poorer QoL compared to baseline). EQ-5D VAS scores and WHO-5 scores also significantly decreased across time indicating a worsening QoL (Additional file [2](#MOESM2){ref-type="media"}: Table S1).Fig. 1Change in QoL over 3 years of follow-up SGRQ (*p* \< 0.001), SGRQ symptoms (*p* = 0.142), SGRQ activity (*p* \< 0.001), SGRQ impacts (*p* \< 0.001), EQ-5D VAS (*p* \< 0.001), UCSD Shortness of breath (*p* \< 0.001), WHO-5 (*p* \< 0.001)) over 3 years of follow-up. EQ-5D VAS, EuroQol five-dimensional questionnaire, recorded as a visual analog scale; QoL, quality of life; SGRQ, St. George's Respiratory Questionnaire; USCD-SOBQ, University of California San Diego Shortness of Breath Questionnaire; WHO-5, World Health Organization-5 Well-Being Index

Details about the association between the different QoL measures and clinical characteristics at baseline and change in clinical parameters in follow-up are reported in Table [2](#Tab2){ref-type="table"}. Female patients reported significant higher, i.e. poorer SGRQ scores during follow-up (beta = 5.42, 95% CI: 1.13 to 9.71; *p* = 0.013) compared to males. A higher NYHA stage, GAP index and a more severe assessment of the clinical course of the patient by the treating physician at baseline were associated with higher, i.e. worse SGRQ scores. The more impaired the lung function was at baseline, the higher were the SQRQ scores during follow-up. Patients with more than a 10% decrease of FVC % predicted and/or DL~CO~ % predicted within 1 year reported significantly worse SQRQ scores during follow-up compared to stable patients; FVC % predicted (beta = 9.08; 95% CI: 2.48 to 15.67; *p* = 0.007); DL~CO~ % predicted (beta = 7.79; 95% CI: 0.85 to 14.73; *p* = 0.028). Comparable results were observed for the other QoL measures (Table [2](#Tab2){ref-type="table"}).Table 2Associations of QoL with clinical parameters at baseline and change in clinical parameters in follow-upSGRQ totalEQ 5D VASUCSD-SOBQWHO-5beta95% CI*p*-valuebeta95% CI*p*-valuebeta95% CI*p*-valuebeta95% CI*p*-valueFemale sex5.421.13; 9.710.013−3.36−6.90; 0.180.06313.566.41; 20.72\< 0.001− 1.47−2.60; − 0.330.011Age0.00−0.19; 0.200.963−0.18− 0.34; − 0.020.0290.350.04; 0.660.026−0.05− 0.10; 0.000.074Age at first symptom onset in years−0.10− 0.28; 0.080.285− 0.08− 0.22; 0.070.3230.17− 0.11; 0.460.238− 0.03− 0.07; 0.020.299Age at diagnosis in years−0.09− 0.28; 0.090.320− 0.08− 0.23; 0.070.2900.18− 0.11; 0.480.227− 0.02− 0.07; 0.030.400Duration since first symptoms in years0.730.28; 1.180.002−0.51−0.89; − 0.130.0080.71− 0.04; 1.460.062− 0.09− 0.21; 0.030.139Disease duration in months1.360.70; 2.02\< 0.001−1.10− 1.65; −0.55\< 0.0011.700.64; 2.770.002−0.25−0.43; − 0.080.005  \< 3 months1.001.001.001.00 3 to \< 6 months−2.63−9.30; 4.040.4401.30−4.28; 6.890.647−4.48−16.06; 7.110.4490.54−1.27; 2.340.560 More than 6 months6.542.53; 10.550.001−5.10−8.43; − 1.760.0038.431.74; 15.120.014−0.68−1.76; 0.400.215Number of comorbidities None1.001.001.001.00 13.55−1.37; 8.470.157−5.19−9.23; − 1.160.0129.932.05; 17.800.013−0.86−2.16; 0.440.195 24.49−0.63; 9.610.086−6.46−10.66; −2.260.00310.111.88; 18.340.016−1.02−2.37; 0.330.140 35.87−0.04; 11.780.051−7.75− 12.62; −2.880.00215.375.74; 24.990.002−1.98−3.55; −0.410.013 4+17.1810.14; 24.23\< 0.001−14.99−20.88; −9.11\< 0.00133.0620.77; 45.35\< 0.001−4.35−6.24; −2.46\< 0.001NHYA I1.001.001.001.00 II16.079.16; 22.98\< 0.001−12.61−19.06; −6.15\< 0.00122.2810.78; 33.77\< 0.001−1.86−3.92; 0.210.078 III26.9519.97; 33.93\< 0.001−18.00−24.49; − 11.50\< 0.00138.2926.65; 49.92\< 0.001−3.82−5.90; − 1.75\< 0.001 IV33.2816.44; 50.13\< 0.001−27.35−41.90; − 12.81\< 0.00151.6324.63; 78.64\< 0.001−8.69−13.43; − 3.95\< 0.0016MWD (m)− 0.01− 0.01; 0.000.2170.000.00; 0.010.313−0.01− 0.03; 0.000.1090.000.00; 0.000.423FEV~1~% predicted−0.55−0.62; − 0.49\< 0.0010.430.37; 0.49\< 0.001− 0.80− 0.91; − 0.70\< 0.0010.090.07; 0.11\< 0.001FVC % predicted− 0.60− 0.66; − 0.53\< 0.0010.460.39; 0.53\< 0.001−0.89−1.00; − 0.78\< 0.0010.110.09; 0.13\< 0.001DL~CO~ % predicted−0.26− 0.31; − 0.20\< 0.0010.260.20; 0.33\< 0.001− 0.35− 0.44; − 0.25\< 0.0010.040.02; 0.06\< 0.001Change in FVC % predicted between baseline and 1-year follow-up Stable/increase1.001.001.001.00 Decrease by 0 to 10%3.71−0.55; 7.970.087−2.90−6.58; 0.770.1224.08−3.13; 11.290.267−0.51−1.67; 0.650.393 Decrease by \> 10%9.082.48; 15.670.007−8.07−13.81; −2.330.00611.240.32; 22.160.044−1.30−3.09; 0.500.156Change in DL~CO~ % predicted between baseline and 1-year follow-up Stable/increase1.001.001.001.00 Decrease by 0 to 10%5.460.85; 10.080.020−0.41−4.43; 3.600.84110.462.85; 18.070.007−0.37−1.62; 0.880.561 Decrease by \> 10%7.790.85; 14.730.028−3.93−9.96; 2.100.20110.74−0.73; 22.210.067−0.40−2.28; 1.470.673Change in FVC % predicted between baseline and last follow-up Stable/increase1.001.001.001.00 Decrease by 0 to 10%3.44−1.04; 7.920.133−3.30−7.08; 0.480.0873.18−4.45; 10.810.414−0.22−1.44; 0.990.719 Decrease by \> 10%7.472.11; 12.830.006−6.50−11.02; − 1.990.0058.80−0.15; 17.750.054−0.87−2.32; 0.590.242Change in DL~CO~ % predicted between baseline and last follow-up Stable/increase1.001.001.001.00 Decrease by 0 to 10%4.41−0.52; 9.350.080−1.42−5.59; 2.750.50511.092.94; 19.230.008−0.44−1.77; 0.890.518 Decrease by \> 10%5.10−0.51; 10.720.075−2.47−7.18; 2.250.3058.24−0.88; 17.360.077−0.30−1.80; 1.210.701GAP index3.291.95; 4.64\< 0.001−3.41−4.50; −2.33\< 0.0016.474.36; 8.58\< 0.001−0.50− 0.86; − 0.140.007 Stage I1.001.001.001.00 Stage II5.690.74; 10.630.024−7.04−11.00; −3.08\< 0.00116.518.69; 24.34\< 0.001−0.92−2.25; 0.410.177 Stage III12.937.42; 18.45\< 0.001−13.51− 17.96; −9.07\< 0.00125.7817.08; 34.47\< 0.001− 1.79−3.27; −0.300.019Overall physician's judgement of clinical course of IPF Stable disease1.001.001.001.00 Slow progression7.793.51; 12.06\< 0.001−3.52−7.14; 0.100.05611.134.04; 18.210.002−1.08−2.23; 0.080.068 Rapid progression13.166.22; 20.11\< 0.001−9.52−15.39; −3.650.00119.898.32; 31.470.001−2.72−4.61; −0.830.005 No judgement possible−0.39−4.93; 4.150.8651.33−2.43; 5.090.4871.72−5.72; 9.150.651−0.01−1.23; 1.200.986*6MWD* six-minute walk distance; beta, regression coefficient, *CI* confidence interval, *DL*~*CO*~ diffusing capacity of the lung for carbon monoxide, *EQ-5D VAS* EuroQol five-dimensional questionnaire, recorded as a visual analog scale, *FEV*~*1*~ Forced expiratory volume in 1 s, *FVC* forced vital capacity, *GAP index* Gender, Age, Physiology index, *IPF* idiopathic pulmonary fibrosis, *NYHA* New York Heart Association functional class, *QoL* quality of life, *SD* standard deviation, *SGRQ* St. George's Respiratory Questionnaire, *USCD-SOBQ* University of California San Diego Shortness of Breath Questionnaire, *WHO-5* World Health Organization-5 Well-Being Index

SGRQ at last follow-up, and change in SGRQ between baseline and last follow-up in association to lung functional changes within 1 year are shown in Fig. [2](#Fig2){ref-type="fig"}. More complete data for the SGRQ and those for all other QoL measures are presented in the online data supplement (Additional file [2](#MOESM2){ref-type="media"}: Table S2). The deterioration in SGRQ scores until last follow-up was associated with a worsening of FVC % predicted and DL~CO~ % predicted within 1 year after enrolment. In patients with stable or even improving, i.e. increasing FVC % predicted, SGRQ scores after 36 months follow-up remained relatively unchanged from baseline (mean − 0.1 units ‡ 21.1) with SGRQ at 36-months of 45.7 units ‡ SD 19.5. In contrast, compared to these patients, those patients with a decline of \> 10% in FVC % predicted reported a significantly higher increase in SQRQ scores from baseline (mean 20.6 ‡19.1, beta = 20.71; 95% CI: 13.09 to 28.33; *p* \< 0.001) and significantly higher SGRQ scores at last follow-up (mean = 64.1 ‡ 19.6, beta = 18.43; 95% CI: 10.98 to 25.87). There was also a non-significant trend towards a worse SGRQ for patients with a moderate lung functional decline compared to stable patients. A similar pattern was seen when comparing patients with a decline of \> 10% in DL~CO~ % predicted with those with stable/improving DL~CO~ % predicted (Fig. [2](#Fig2){ref-type="fig"}). Similar associations were also seen for other QoL scores (SQRQ symptom, activity and impact domains, and UCSD-SOBQ, EQ-5D, WHO-5) (Online data supplement; Additional file [2](#MOESM2){ref-type="media"}: Table S2).Fig. 2QoL at last follow-up visit and Change in QoL from baseline to last follow-up visit by change in lung function. \* *p*-value \< 0.05 in comparison to category 'stable/ increase' DL~CO~ % predicted: diffusing capacity of the lung for carbon monoxide % predicted; FVC % predicted, forced vital capacity % predicted; QoL, quality of life; SGRQ, St. George's Respiratory Questionnaire

Association of QoL and mortality {#Sec9}
--------------------------------

Over the study period there were 113 deaths (26.7% of all included patients). Univariate analysis found that change from baseline to last visit in any QoL outcome scores (i.e., SGRQ total score, UCSD-SOBQ, EQ-5D VAS, and WHO-5) were each predictive of mortality (Fig. [3](#Fig3){ref-type="fig"}). Patients who died during follow up in this cohort had a significant greater increase in SGRQ total scores from baseline to their last follow-up visit prior to death (mean 11.8 ± 18.6) compared to surviving patients (mean 4.2 ± 18.9; HR = 1.03; 95% CI: 1.02 to 1.05; *p* \< 0.001). Changes from baseline in UCSD-SOBQ scores in patients who died and survivors were 7.0 ± 29.1 and 20.4 ± 1.5 respectively; HR = 1.03; 95% CI: 1.01 to 1.04; *p* \< 0.001. In patients who died, the SGRQ and UCSD-SOBQ scores reported at last follow-up visit were all significantly higher (and EQ-5D VAS, and WHO-5 scores significantly lower) compared to surviving patients (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Association of QoL at last follow-up and change in QoL between baseline and last follow-up with mortality. Light grey and dark grey bares indicate patients who are censored and died during the observation period, respectively. Hazard ratios adjusted for QoL at baseline. EQ-5D VAS, EuroQol five-dimensional questionnaire, recorded as a visual analog scale; HR, Hazard ratio; QoL, quality of life; SGRQ, St. George's Respiratory Questionnaire; USCD-SOBQ, University of California San Diego Shortness of Breath Questionnaire; WHO-5, World Health Organization-5 Well-Being Index

After adjusting for change in FVC% predicted, age, number of comorbid diseases, hospitalisation during follow-up and the physician's global assessment about the disease course, multivariate analysis found that a lower QoL at last available follow-up was significantly associated with mortality (Table [3](#Tab3){ref-type="table"}). When evaluating mortality and SGRQ scores at last available follow-up, higher age (HR = 1.06; 95% CI: 1.03 to 1.09; *p* \< 0.001) and a \> 10% decline in FVC % predicted (HR = 2.34, 95% CI: 1.18 to 4.62; *p* = 0.015) were each associated with mortality. Furthermore, the higher the number of comorbid diseases the higher the risk for mortality (none versus one: HR = 2.40, 95% CI: 1.15 to 5.01; *p* = 0.02; none versus two: HR = 2.10, 95% CI: 1.02 to 4.32; *p* = 0.043; none versus three: HR = 2.78, 95% CI: 1.26 to 6.09; *p* = 0.011). Comparable results were found for the other QoL measures at last follow-up. In contrast, no significant associations between change from baseline to last available follow-up in QoL scores and mortality were observed in multivariate analysis (Table [3](#Tab3){ref-type="table"}).Table 3Multivariable association of A) QoL at last available follow-up and B) change in QoL between Baseline and last available follow-up and clinical characteristics with mortalitySGRQ totalEQ-5D VASUCSD-SOBQWHO-5HR95% CI*p*-valueHR95% CI*p*-valueHR95% CI*p*-valueHR95% CI*p*-value*A)* Multivariable model including QoL at last available follow-up QoL at last available follow-up ^a^1.121.06; 1.18\< 0.0010.910.87; 0.960.0011.141.08; 1.20\< 0.0010.830.69; 0.990.048 Age ^a^1.321.14; 1.54\< 0.0011.301.12; 1.510.0011.271.09; 1.480.0021.251.07; 1.460.006 Number of comorbidities  01.001.001.001.00  12.401.15; 5.010.021.930.98; 3.770.0572.510.92; 6.810.0712.030.93; 4.410.075  22.101.02; 4.320.0431.620.83; 3.190.1612.400.90; 6.400.0792.241.05; 4.800.038  32.781.26; 6.090.0112.151.02; 4.530.0433.160.99; 10.050.0522.310.97; 5.460.057  4+1.950.69; 5.490.2051.980.77; 5.070.1551.300.29; 5.860.7342.801.00; 7.860.051 Change in FVC % predicted  Stable/increase1.001.001.001.00  Decrease by 0 to 10%1.630.98; 2.710.0581.600.97; 2.640.0661.410.75; 2.640.2861.751.01; 3.030.047  Decrease by \> 10%2.341.18; 4.620.0152.291.16; 4.510.0172.140.87; 5.260.0962.701.32; 5.530.007 Hospitalisation1.260.80; 1.970.3221.540.98; 2.400.061.000.57; 1.740.9941.290.81; 2.060.286 Overall physician's judgement of clinical course of IPF  Stable disease1.001.001.001.00  Slow progression1.480.92; 2.380.1061.701.08; 2.690.0221.300.71; 2.370.3991.911.16; 3.170.012  Rapid progression0.970.46; 2.040.9331.180.55; 2.530.6741.060.46; 2.420.8961.250.53; 2.950.617  No judgement possible0.890.46; 1.740.7430.980.52; 1.840.951.260.54; 2.930.5880.940.47; 1.910.871B) Multivariable model including change in QoL between baseline and last available follow-up Change in QoL between baseline and last available follow-up ^a^1.050.98; 1.130.1480.970.91; 1.040.3641.070.98; 1.160.1270.850.68; 1.070.165 Age ^a^1.301.11; 1.520.0011.311.12; 1.530.0011.261.02; 1.560.0311.261.07; 1.480.006 Number of comorbidities  01.001.001.001.00  11.980.97; 4.040.0611.830.92; 3.630.0842.030.71; 5.840.1871.930.89; 4.200.096  21.850.90; 3.790.0921.700.85; 3.400.1352.010.65; 6.210.2262.140.99; 4.630.054  32.401.10; 5.240.0282.251.06; 4.760.0353.681.17; 11.550.0262.180.91; 5.230.082  4+2.040.75; 5.570.1652.270.87; 5.920.0931.540.26; 9.060.6342.991.09; 8.220.034 Change in FVC % predicted  Stable/increase1.001.001.001.00  Decrease by 0 to 10%1.691.02; 2.820.0441.650.99; 2.760.0551.110.57; 2.140.7621.670.95; 2.910.073  Decrease by \> 10%2.161.08; 4.310.0292.261.14; 4.500.021.720.71; 4.140.2272.431.18; 5.000.015 Hospitalisation1.350.85; 2.130.2021.540.98; 2.420.0591.300.68; 2.450.4271.300.81; 2.080.285 Overall physician's judgement of clinical course of IPF  Stable disease1.001.001.001.00  Slow progression1.691.05; 2.730.031.831.14; 2.940.0121.380.67; 2.850.3811.891.15; 3.120.013  Rapid progression1.420.69; 2.910.3411.630.76; 3.460.2071.270.47; 3.410.6361.380.61; 3.120.439  No judgement possible0.970.49; 1.920.9220.960.50; 1.830.9021.240.52; 2.950.6220.830.39; 1.770.635*CI* confidence interval, *EQ-5D VAS* EuroQol five-dimensional questionnaire, recorded as a visual analog scale, *HR* hazard ratio, *FVC* forced vital capacity, *IPF* idiopathic pulmonary fibrosis, *QoL* quality of life, *SD* standard deviation, *SGRQ* St. George's Respiratory Questionnaire, *USCD-SOBQ* University of California San Diego Shortness of Breath Questionnaire, *WHO-5* World Health Organization-5 Well-Being Index^a^ HR for increase by 5 points on the QoL scale or by 5 years of ageTable 4Multivariable association of QoL and clinical characteristics with any hospitalizations and hospitalizations due to exacerbations in follow-upSGRQEQ-5D VASUCSD-SOBQWHO-5beta95% CI*p*-valuebeta95% CI*p*-valuebeta95% CI*p*-valuebeta95% CI*p*-valueAny hospitalisation3.950.35; 7.560.032− 0.53−3.70; 2.640.7438.412.46; 14.370.006−0.56− 1.60; 0.480.292Age−0.04− 0.26; 0.170.702− 0.21− 0.39; − 0.020.0260.26− 0.08; 0.610.129− 0.05− 0.11; 0.020.141Number of comorbidities 00.000.000.000.00 1−1.61−7.37; 4.150.584−0.40−5.40; 4.600.8750.31−8.64; 9.260.9460.29−1.25; 1.830.714 21.82−3.91; 7.560.533−3.01−8.19; 2.170.2555.47−3.72; 14.660.2430.20−1.36; 1.760.801 33.36−2.91; 9.620.293−4.07−9.51; 1.380.1437.11−2.70; 16.930.155−0.96−2.63; 0.710.259 4+11.424.99; 17.850.001−10.18− 16.28; −4.070.00122.9611.27; 34.65\< 0.001−2.64−5.02; −0.270.029Change in FVC % predicted Stable/increase0.000.000.000.00 Decrease by 0 to 10%3.70−0.10; 7.510.057−2.93−6.17; 0.320.0774.60−1.67; 10.870.151−0.51−1.62; 0.610.375 Decrease by \> 10%8.082.23; 13.930.007−6.11−11.14; − 1.080.0178.91−0.23; 18.050.056−0.97−2.59; 0.660.242Overall physician's judgement of clinical course of IPF Stable disease0.000.000.000.00 Slow progression7.154.88; 9.42\< 0.001−7.24− 10.05; −4.44\< 0.00110.655.96; 15.35\< 0.001−1.62−2.34; − 0.89\< 0.001 Rapid progression22.6816.83; 28.52\< 0.001− 26.37−32.73; − 20.01\< 0.00133.5724.66; 42.48\< 0.001−6.35−8.31; −4.40\< 0.001 No judgement possible3.020.33; 5.700.027−2.15−5.16; 0.870.1631.70−2.96; 6.350.475−1.25−2.11; −0.400.004Hospitalisation by exacerbation5.350.64; 10.070.026−1.56−5.78; 2.650.46810.892.72; 19.050.009−0.78−2.32; 0.760.320Age0.04−0.24; 0.310.791−0.37− 0.59; − 0.150.0010.40− 0.02; 0.820.062− 0.04−0.12; 0.040.383Number of comorbidities 00.000.000.000.00 1−0.33−6.99; 6.320.922−1.35−7.22; 4.510.6511.41−8.79; 11.610.7860.23−1.58; 2.040.804 22.93−3.86; 9.720.397−2.43−8.49; 3.640.4336.77−4.36; 17.890.233−0.09−2.05; 1.880.930 33.52−3.89; 10.930.352−1.79−8.17; 4.600.5837.09−5.08; 19.270.253−0.94−3.15; 1.260.403 4+13.155.95; 20.36\< 0.001−8.90−15.99; − 1.820.01421.078.29; 33.840.001−2.60−5.56; 0.360.085Change in FVC % predicted Stable/increase0.000.000.000.00 Decrease by 0 to 10%4.08−0.73; 8.880.096−4.12−8.39; 0.150.0596.63−1.24; 14.500.099−0.75−2.17; 0.670.300 Decrease by \> 10%7.490.66; 14.320.032−4.05−10.00; 1.900.1829.98−0.91; 20.860.072−1.04−2.79; 0.720.247Overall physician's judgement of clinical course of IPF Stable disease0.000.000.000.00 Slow progression6.653.84; 9.46\< 0.001−8.90−12.49; −5.31\< 0.0019.983.38; 16.580.003−1.63−2.55; −0.700.001 Rapid progression24.2317.19; 31.26\< 0.001−27.75−36.15; −19.34\< 0.00133.7822.82; 44.75\< 0.001−6.67−9.06; −4.29\< 0.001 No judgement possible2.36−0.77; 5.490.139−1.16−4.97; 2.660.552−0.76−6.46; 4.940.794−0.98−2.00; 0.030.058*beta* regression coefficient, *CI* confidence interval, *EQ-5D VAS* EuroQol five-dimensional questionnaire, recorded as a visual analog scale, *FVC* forced vital capacity, *IPF* idiopathic pulmonary fibrosis, *QoL* quality of life, *SD* standard deviation, *SGRQ* St. George's Respiratory Questionnaire, *USCD-SOBQ* University of California San Diego Shortness of Breath Questionnaire, *WHO-5* World Health Organization-5 Well-Being Index

Association of QoL and hospitalisation and exacerbations {#Sec10}
--------------------------------------------------------

Over the study period 227 patients were hospitalised for any cause and 31 hospitalised for exacerbations. Univariate and multivariate analysis found that the mean SGRQ and UCSD-SOBQ scores across the follow-up period were all significantly higher (and for univariate analyses EQ-5D VAS, and WHO-5 score significantly lower) in hospitalised patients compared to non-hospitalised patients, with the highest mean SGRQ and UCSD-SOBQ scores throughout follow-up (and lowest EQ-5D VAS and WHO-5 scores) reported in those hospitalised for IPF (Table [4](#Tab4){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}). Furthermore, across the follow-up period an overall trend was observed, in which successively greater increases in mean SGRQ and UCSD-SOBQ scores and successively greater reductions in EQ-5D VAS and WHO-5 scores were reported by patients hospitalised on 1, 2, 3 and ≥ 4 separate occasions (Online data supplement; Additional file [3](#MOESM3){ref-type="media"}: Figure S1).Fig. 4Mean QoL scores for patients who were hospitalized (dark grey bares) during follow-up compared to patients who were not hospitalized (light grey bares). EQ-5D VAS, EuroQol five-dimensional questionnaire, recorded as a visual analog scale; QoL, quality of life; SGRQ, St. George's Respiratory Questionnaire; USCD-SOBQ, University of California San Diego Shortness of Breath Questionnaire; WHO-5, World Health Organization-5 Well-Being Index

Hospitalisation had an adverse impact upon subsequent QoL. Following hospitalisation, significantly higher mean SGRQ scores (total scores and activity and impacts domain scores) and higher mean UCSD-SOBQ scores were reported at the subsequent follow-up visit compared to those reported at the visit prior to hospitalisation (and significantly lower mean EQ-5D VAS and WHO-5 scores) (Online data supplement; Additional file [2](#MOESM2){ref-type="media"}: Table S3).

Discussion {#Sec11}
==========

According to the present data, collected from a representative setting of centres with expertise in the management of patients with IPF, a close relationship between QoL and clinical outcomes were found; including clinically meaningful changes in lung function, comorbidities, disease duration and clinical course of IPF (including hospitalisation, acute exacerbations and mortality). For these analyses, we used a range of QoL assessments which, although not originally designed for IPF, have data to support their validity in this patient population, as shown in our previous report and by others \[[@CR6], [@CR7], [@CR9], [@CR15]--[@CR18]\]. The optimal tool for QoL assessment in IPF patients remains to be determined, with an adaptation of the SGRQ specifically for use in IPF not yet fully validated or in widespread use \[[@CR19]\], while other more focused IPF QoL-measures are also in use or being developed for use (e.g. the Kings' Brief Interstitial Lung Disease health status \[K-BILD\] and the 'A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis \[ATAQ-IPFcA\] questionnaires) \[[@CR9], [@CR20], [@CR21]\]. It is likely that, while subtle differences may exist, most current tools assess QoL with similar sensitivity and with high or very high correlation between most questionnaires \[[@CR7], [@CR9]\].

To our knowledge, the only previous report on longitudinal assessments of QoL in IPF patients in clinical practice comes from the Australian IPF registry in a somewhat smaller dataset \[[@CR6]\]. In that study, a strong relationship between decline in FVC % predicted and decline in QoL was shown, with QoL impairment mainly due to dyspnoea (measured using the SGRQ and UCSD-SOBQ scores) although cough and depression (assessed by a VAS scale and the Hospital Anxiety and Depression Scale (HADS)) also contributed \[[@CR6]\]. While in that study, no association between baseline QoL measures and mortality was found, a more recent report from the Australian registry indicates that in those patients with mild physiological impairment (FVC ≥ 80%), baseline SGRQ and UCSD-SOBQ scores are predictive of mortality, with HRs of 1.11 (95% CI: 1.06 to 1.15) and 1.23 (95% CI: 1.13 to 1.33) respectively (*p* \< 0.001 for both) \[[@CR22]\]. In contrast to the Australian Registry, we found a significant relationship between lower QoL at last available follow-up but no significant association (on multivariable analysis) between mortality and change in QoL for the total IPF population. Number of comorbidities as well as hospitalisations were driving this QoL decline. Notably, significant changes in both FVC and DLco % predicted values closely reflected changes in QoL indicating that stabilising lung function may also halt decline of QoL in IPF.

The overall pattern we observed across the cohort was a longitudinal decline in QoL. How then can we seek to improve upon or at least maintain patient QoL in clinical practice? At present, only sparse data on the long-term effects of available therapies on QoL outcomes exist. While disease stabilisation by antifibrotic therapies may offer some potential in maintaining QoL (or retarding decline), available data to support this goal remain limited. In the pivotal phase 3 trials evaluating nintedanib and pirfenidone (each versus placebo), no significant differences in changes in SGRQ scores (from baseline to 52 weeks) were seen between the treatment and placebo arms \[[@CR23], [@CR24]\] a finding which could be due to side effects or to short observation times. Furthermore, this has also to be interpreted in light of the here reported differences in associations of QoL to lung functional decline which was statistically significant comparing stable to significantly progressing patients, i.e. with a decrease of FVC \> 10%. However, the difference to moderately progressive patients, i.e. a decline between 0 and 10% was only by trend. In the INPULSIS trials for example adjusted absolute mean change from baseline in FVC% was also within this range with − 2.8 for nintedanib and − 6.0 for placebo. Still, a subsequent pooled analysis of the TOMORROW and INPULSIS trials comparing nintedanib vs. placebo has shown that the reduction in annual FVC % predicted decline seen in the nintedanib arms was accompanied by lower increases in SGRQ compared to placebo (with a mean difference in adjusted mean change from baseline of − 2.05 \[95% CI: --3.59 to − 0.50\]; *p* \< 0.0095) \[[@CR25]\]. In the step-IPF study, sildenafil was reported to positively impact upon QoL in IPF patients with severe impairment of gas exchange (i.e. DLco ≤35%) \[[@CR26]\]. In a recent randomised controlled trial using nintedanib and sildenafil in combination (INSTAGE study) a positive, while non-significant trend on QoL was observed, but conclusive data is still lacking \[[@CR27]\]. On balance, it is likely that optimising pharmacotherapy in IPF patients (and reducing decline in lung function) may also assist in improving QoL in IPF patients. As groups in cohort studies like ours, e.g. with and without antifibrotic therapies, inevitably differ in their clinical characteristics comparisons of therapy effects on QoL in registries may be subject to bias by indication. We therefore refrained from performing comparative analyses with regards to therapy, which however should be assessed in future research.

Non-pharmacotherapy treatments are also important. As physical activity is a strong predictor of IPF disease course, methods to increase physical activity e.g., pulmonary rehabilitation are important in prolonging a more positive life-span, in particular as data suggests that pulmonary rehabilitation may increase QoL \[[@CR28]--[@CR30]\]. Allied to this, greater attention to assessment and treatment of comorbid conditions may improve or at least alleviate longitudinal decline in QoL, although as of yet this remains unproven \[[@CR4]\]. For several patients, early palliative care may be an appropriate approach \[[@CR5], [@CR12]\].

Our study has a number of limitations (above that of using non-IPF specific QoL measures as discussed above). Typically for data collection under clinical practice conditions, sites showed considerable variance in terms of number of documented visits and visit time-points, and in terms of completeness of data (each depending on their routine clinical schedule) including QoL reports. Furthermore, a potential bias cannot be excluded, such as underreporting or underdiagnosing of subacute deterioration and any influence of social factors (e.g., family situation) and other aspects external to the disease process. A high number of patients enrolled were excluded from the present analyses due to incomplete data of longitudinal QoL assessment. As some differences had been noted between the group of in- and excluded patients, e.g. a more severe disease and a higher mean number of comorbidities, a bias of our results toward patients with a more severe disease course cannot be excluded. In addition, not every patient completed each of the QoL questionnaires at least yearly as stipulated. However, the relatively large numbers of included patients and completed QoL measures in connection with a long follow-up period do provide a substantially large sample and exposure time from which we found significant differences in a number of outcomes, and association of QoL changes with clinical status. A final limitation is that we have not included potential effects of treatment (including use of anti-fibrotic agents) in the present analyses and cannot report on benefits of such treatment.

Conclusions {#Sec12}
===========

In conclusion, we found strong associations of changes of QoL to important outcomes in IPF; principally decline in lung function, hospitalisation for acute exacerbations and mortality. Pharmacological and non-pharmacological therapies used to reduce these clinically important events should also aim to maintain or even improve QoL as assessed by these equally important patient-reported outcomes.
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:   Six-minute walk distance

DL~CO~

:   Diffusing capacity of the lung for carbon monoxide

EQ-5D VAS

:   EuroQol five-dimensional questionnaire, recorded as a visual analog scale

FEV~1~

:   Forced expiratory volume in 1 s

FVC % predicted

:   Forced vital capacity % predicted

GAP index

:   Gender, Age, Physiology index

NYHA

:   New York Heart Association functional class

SGRQ

:   St. George's Respiratory Questionnaire

USCD-SOBQ

:   University of California San Diego Shortness of Breath Questionnaire

WHO-5

:   World Health Organization-5 Well-Being Index
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